CD80 and pancreatic neoplasm: In order to show the regulatory effect of our nanomedicine on macrophage phenotypes, we analyzed the CD80+ (M1-like) and CD206+ (M2-like) populations in the F4/80+ macrophages from the treated pancreatic tumors (Fig. 4f–i).